When Merck & Co. pulled Vioxx from pharmacy shelves worldwide on 30 September 2004, chief executive Raymond Gilmartin framed it as a responsible company acting on new data; the documented record shows a five-year gap between that posture and what the company’s own clinicians had measured. Vioxx (rofecoxib), a COX-2 selective anti-inflammatory approved by the U.S. Food and Drug Administration on 20 May 1999 and marketed as a gentler painkiller that spared the stomach, was instead associated with one of the largest drug-safety catastrophes in regulatory history. FDA drug-safety reviewer David Graham would testify to the Senate Finance Committee on 18 November 2004 that the drug had caused on the order of 88,000 to 139,000 excess heart attacks and strokes in the United States, of which perhaps 30 to 40 percent were fatal — a toll he compared to between two and four jumbo-jet crashes a week sustained over five years.
The gap between promise and reality was not discovered late; it was visible in Merck’s own trials. The VIGOR study, published in The New England Journal of Medicine on 23 November 2000 under lead author Claire Bombardier, showed that the 8,076 patients taking rofecoxib had roughly four to five times the rate of myocardial infarction of patients taking the older drug naproxen — a relative risk the published paper reported as 0.2 in naproxen’s favor. Merck attributed the difference to a supposed protective effect of naproxen rather than a cardiac hazard of Vioxx — a hypothesis that was never proven and that the company continued to advance while sales climbed past $2.5 billion a year and a sales force of more than 3,000 representatives carried the message to prescribers.
The withdrawal came only when the harm became impossible to explain away. The APPROVe trial — designed to test whether Vioxx prevented recurrent colon polyps, not to study the heart — was halted early on 23 September 2004 after showing that rofecoxib roughly doubled the risk of confirmed cardiovascular events after eighteen months of use, against placebo. The verdict here is therefore plain at the outset: an approved, heavily advertised, trusted medicine reached tens of millions of patients while the signal that would eventually condemn it sat in the company’s data, the FDA’s review files, and the medical literature, fully legible to anyone with access and the will to read it.
What followed was the largest pharmaceutical mass-tort reckoning of its era. In November 2007 Merck agreed to pay $4.85 billion to resolve roughly 27,000 lawsuits covering some 47,000 plaintiff groups, NEJM issued a formal “Expression of Concern” alleging the VIGOR authors had withheld cardiac data, and the case became the standard byword for how surrogate-endpoint approval, aggressive marketing, and suppressed safety signals can converge into mass harm before any regulator pulls the cord.
When Bayer AG voluntarily withdrew Baycol (cerivastatin) from the worldwide market on 8 August 2001, the company described it as a precaution against a rising “reporting rate” of muscle injury; the documented record shows that the latecomer statin had already been associated with fatal rhabdomyolysis at roughly forty to fifty times the rate of its competitors, a hazard that was foreseeable from its known pharmacology and visible in adverse-event data well before the recall. Cerivastatin, the sixth statin to reach the U.S. market and approved by the Food and Drug Administration in June 1997, was promoted as a potent, low-dose entrant in an already crowded class. It captured slightly under 4 percent of the U.S. statin market — and yet, by the FDA’s own count at withdrawal, it accounted for 31 American deaths from rhabdomyolysis, a condition in which skeletal muscle disintegrates, floods the bloodstream with myoglobin, and shuts down the kidneys.
The gap between promise and reality was not a matter of rare bad luck. In an analysis by FDA scientists, the relative reporting rate of fatal rhabdomyolysis was on the order of forty times higher for cerivastatin than for the other approved statins; for all rhabdomyolysis, fatal and nonfatal, the figure was roughly fifty-four times higher. The danger was concentrated and predictable: it rose with the 0.8 mg high dose Bayer had introduced to compete on potency, rose in elderly patients, and rose catastrophically when cerivastatin was combined with gemfibrozil, a fibrate that interfered with the drug’s clearance. Twelve of the 31 U.S. deaths involved that very combination — a combination Bayer had contraindicated on the label, but which physicians prescribed in numbers the warning failed to suppress.
The withdrawal came only when the body count made the signal undeniable. The verdict here is therefore plain at the outset: an approved cholesterol drug holding a minority share of its market produced a disproportionate share of its class’s fatal harm, because a known drug-interaction hazard and an aggressive high-dose strategy were allowed to reach roughly six million patients while the contraindication label substituted for the market action the data warranted.
What followed was a transatlantic litigation reckoning. Bayer faced on the order of 7,800 product-liability suits in the United States alone — a figure that grew past 12,000 — and ultimately paid well over $1 billion to settle claims, while internal documents pried loose in discovery showed company scientists had flagged the gemfibrozil danger and the rising death reports before the recall. Baycol became the standard cautionary case for how a “me-too” drug competing on potency can convert a known interaction into mass casualties.
When the U.S. Food and Drug Administration asked Warner-Lambert to pull Rezulin from the market on 21 March 2000, it ended a three-year arc in which a celebrated first-in-class diabetes pill killed at least 63 people through liver failure while the warning that should have stopped it had been visible from before launch. Rezulin (troglitazone), the first thiazolidinedione — an oral “insulin sensitizer” acting on the PPAR-gamma receptor — was approved on 29 January 1997 and marketed as a breakthrough that let type 2 diabetics use their own insulin more effectively. The gap between that promise and the harm was not subtle: the drug produced idiosyncratic, sometimes fulminant hepatotoxicity, and Britain’s Glaxo Wellcome withdrew it from the U.K. market on 1 December 1997 — barely ten months after the U.S. approval — while the FDA kept it on American shelves for another twenty-eight months.
The signal was institutional, not merely clinical. The FDA medical officer originally assigned to the application, Dr. John Gueriguian, had recommended against approval over cardiac and liver concerns; he was removed from the review on 4 November 1996, and his negative analysis was purged from the official record before the drug was cleared on an expedited timeline. Within the first year of marketing, serious hepatotoxicity reports accumulated, and an internal FDA memorandum cited 135 reports of serious liver injury by late 1997. Public Citizen’s Health Research Group, led by Dr. Sidney Wolfe, petitioned for withdrawal in July 1998, asking the agency how many more Americans would have to die or need transplants.
The verdict is therefore plain at the outset: a profitable, regulator-blessed, heavily prescribed medicine reached nearly two million Americans while the evidence that condemned it — a foreign withdrawal, a buried internal review, mounting death reports, and an outside petition — sat fully legible in the record. The FDA’s response was incrementalism: four label changes between 1997 and 1999 adding ever-stricter liver-monitoring instructions that real-world prescribing could not reliably execute, rather than removal.
What finally forced the withdrawal was arithmetic the labels could not fix. Once two safer thiazolidinediones — rosiglitazone and pioglitazone — reached the market in 1999 without the same fatal liver signal, Rezulin’s risk-benefit case collapsed, and the FDA requested its removal on 21 March 2000. Litigation followed: Warner-Lambert, absorbed by Pfizer in 2000, ultimately resolved roughly 35,000 claims for an estimated $750 million, and “Rezulin” became a byword for how a buried safety review and an ignored foreign recall can keep a lethal drug on the market for years.
When Wyeth-Ayerst Laboratories pulled Duract from American pharmacies on 22 June 1998, the company cast it as a precaution against rare liver events in patients who had overstayed a clearly printed 10-day limit; the documented record shows the hepatic hazard was visible inside the drug’s own approval file nearly a year earlier, and that an FDA medical officer had argued — and lost — for a boxed warning before a single prescription was written. Duract (bromfenac sodium), a short-term non-steroidal anti-inflammatory approved by the U.S. Food and Drug Administration on 15 July 1997 for acute pain lasting ten days or less, instead became one of the fastest market withdrawals of the modern era. In roughly eleven months it generated some 2.5 million prescriptions and was associated with at least four deaths and eight liver transplants from fulminant hepatic failure, plus a further dozen serious liver injuries, with the count of severe drug-induced liver injury cases ultimately climbing past fifty.
The gap between promise and harm was not a post-market surprise. Bromfenac’s submission already showed that roughly 15 percent of short-term trial patients developed elevations of the liver enzymes AST or ALT to three times the upper limit of normal — a signal of hepatocellular stress markedly greater than that seen with comparable NSAIDs. The FDA medical reviewer who read that data advocated a black-box warning as a condition of approval and was overruled; the drug shipped instead with a routine label and a duration cap of ten days, on the theory that limiting exposure would contain the risk.
That theory collapsed against ordinary prescribing behavior. Acute pain frequently does not resolve in ten days, refills were written, and patients took bromfenac for weeks. The cases that killed and transplanted clustered almost entirely in this extended-use population — the precise scenario the 10-day rule was meant to prevent but had no mechanism to enforce. The verdict here is therefore plain at the outset: an approved, branded analgesic reached millions while the hepatotoxic signal that would condemn it sat fully legible in the agency’s own pre-approval review.
What followed was a rapid, near-total revocation. Wyeth strengthened the warnings in February 1998, the harm continued, and the company withdrew the drug in June; the FDA later formally rescinded the New Drug Application. The molecule survived only by abandoning the bloodstream — reformulated years later as a topical eye drop, where systemic exposure was negligible — while “Duract” became a byword for a withdrawal whose justification had been written before the launch.
When Joseph Califano, Secretary of Health, Education and Welfare, signed the order suspending phenformin on 25 July 1977, he was invoking a power Congress had granted the Food and Drug Administration fifteen years earlier and which no official had ever used: the declaration that an approved medicine was an “imminent hazard to the public health.” Phenformin (phenethylbiguanide), synthesized in 1957 by a team including Seymour Shapiro at the U.S. Vitamin Corporation and marketed in the United States from 1959 by Ciba-Geigy as DBI, had been prescribed to control adult-onset diabetes for nearly two decades. It was withdrawn not because it failed to lower blood sugar — it did that adequately — but because it could quietly poison the body with lactic acid, a complication that killed roughly one of every two patients it reached.
The gap between the promise and the harm was the gap between a surrogate benefit and a survival outcome. Phenformin reliably reduced glycemia, the number physicians could see on a chart; what it did not reliably do was keep patients alive. The biguanide’s mechanism — pushing cellular metabolism toward anaerobic glycolysis — produced excess lactate, and in patients with even modest kidney or heart impairment that lactate could accumulate into a metabolic catastrophe. Phenformin-associated lactic acidosis ran at roughly 40 to 64 cases per 100,000 patient-years, and once it occurred it was fatal in approximately half of cases. The drug treated a chronic disease by trading a visible, manageable problem for an occasional, lethal one.
The verdict was therefore plain long before the suspension. As early as 1959 — the same year U.S. marketing began — the literature linked biguanides to lactic acidosis. In 1971 the federally funded University Group Diabetes Program (UGDP) terminated its phenformin arm after finding excess total and cardiovascular mortality, roughly double that of the placebo and insulin groups combined. By October 1976 the FDA’s own Endocrinology and Metabolism Advisory Committee had recommended removal. The harm sat in the published record for years while ~385,000 Americans were still taking the drug in 1977.
What forced the cord was not the agency but a consumer group and a lawyer’s petition. Ralph Nader’s Health Research Group petitioned for suspension on 22 April 1977; Califano acted in July; the drug was off the U.S. market by 15 November 1978. The episode became the founding precedent for emergency drug suspension, the cautionary prologue to its safer sister biguanide metformin, and the textbook case of how a medicine can be effective on the metric it was sold on and still be a net killer.